Compare Fabrinet (FN) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fabrinet vs Sanofi SA — how do they compare? Fabrinet trades at $460.58 (market cap $17.44B), while Sanofi SA trades at $44.11 (market cap $103.94B). The key difference: Sanofi SA is far larger — about 6× Fabrinet's market cap, and Sanofi SA pays a 5.54% dividend while Fabrinet pays none. Which is the better fit depends on your goals.
| FN | SNY | |
|---|---|---|
Market Cap | $17.44B | $103.94B |
Sector | Technology | Health |
52-Week High | $746.47 | $52.34 |
52-Week Low | $277.04 | $41.33 |
Enterprise Value | $16.50B | $120.43B |
Dividend Yield | — | 5.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fabrinet (FN) trades at $460.16, down 4.69% with a bearish technical signal despite strong fundamentals. The company reported consistent earnings beats with Q1 2026 EPS of $3.72 exceeding expectations, driven by 39% YoY revenue growth in optical communications. Analyst consensus remains strongly bullish with 18 buy ratings and a $733 price target, though technical indicators show selling pressure with support at $448.
The outlook remains positive given Fabrinet's strategic position in AI infrastructure and optical communications, with projected revenue growth to $4.2B in 2026. Key risks include premium valuation multiples and supply chain constraints, but the debt-free balance sheet and expanding margins support long-term growth potential in the AI-driven data center market.
Sanofi (SNY) trades at $44.11, up 2.15% today, with a bullish technical signal supported by moving averages. The company shows strong fundamentals with a P/E of 19.37, net income margin of 15.95%, and consistent earnings beats in recent quarters. Recent FDA approval for Sarclisa's subcutaneous formulation and EU clearance for Cenrifki highlight pipeline progress, while a dividend of $2.42 per share underscores shareholder returns.
Outlook remains positive driven by Dupixent growth and new drug approvals, though risks include EU antitrust probes and competitive pressures. Analysts are mixed with 44% buy ratings, suggesting cautious optimism. The stock presents value with solid cash flow and profitability, but investors should monitor regulatory developments and pipeline execution for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fabrinet
Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.
Read more on FN →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
